Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol

Table 3 Comparison of lipid profile between type 2 diabetes patients with LDL-c within and above target - reclassification according to the 2019 guidelines

	n	LDL-c within target	n	LDL-c above target	p
LDL-c (mg/dL)	16	55.5 (49–66)	80	104.5 (85.3–128.8)	< 0.001
Total cholesterol (mg/dL)	16	143 (125.8–150.8)	80	177 (159–213)	< 0.001
ApoB (mg/dL)	13	70 (54.5–86.5)	75	83 (70–106)	0.037
ApoA1 (F) (mg/dL)	3	160 (NA)	32	157.5 (140.3–180.8)	0.976
ApoA1 (M) (mg/dL)	9	135 (107.5–145.0)	39	134 (115–140)	0.792
ApoB/ApoA1 ratio	12	0.56 (0.39–0.68)	70	0.60 (0.51–0.74)	0.172
Non-HDL-c* (mg/dL)	16	95.5 (84.3–117.3)	80	138 (115.0–164.8)	< 0.001
Oxidized LDL-c* (U/L)	16	113.8 (76.2–160.2)	80	148 (113.9–185.5)	0.024
*Lipoprotein (a) (mg/dL)**	10	6 (4.0–25.8)	74	24.5 (5.0–53.5)	0.232

Data are presented as mean ± standard deviation, unless otherwise indicated by ∗ corresponding to data presented as median, 25th and 75th percentiles. LDL-c Low-density lipoprotein cholesterol, ApoB Apolipoprotein B, ApoA1 Apolipoprotein A1, NA not applicable, M male, F female, Non-HDL-c non-high-density lipoprotein cholesterol

ISSN: 1476-511X